The decision positions the Celgene-backed cancer immunotherapy biotech to move oral small molecule FLX475 into the clinic later this year.
After a $28 million financing, Provention Bio has grabbed two IBD candidates from Janssen that should make it a double clinical-stage biotech in 2018.
For pharma and biotech, in which data is the most valuable asset, industry analysts agree that digital transformation presents an opportunity to realize…
Researchers at Sanofi and the NIH have published preclinical evidence showing that a three-pronged approach may prevent HIV in healthy people.
Researchers at Duke University developing a glioblastoma treatment based on poliovirus are unraveling the process by which the virus fights malignancy.
VC Lightstone has $250 million in the bank for life science research.
Iontas will use its phage display libraries and other antibody discovery capabilities to provide Glythera with a key component of its planned ADCs.
Arcus has signed a deal with Taiho that provides a healthy cash injection while keeping rights in the U.S. and other markets in hand.
XW Laboratories has seen a $17.5 million series B, bumping up its total raise from its first round to $23 million.
The clean sweep is a big win for Alnylam and the Sanofi-partnered RNAi drug, which is now set to be put before regulators at the end of the year.
Eric Carlson, Ph.D., has become the latest in a string of former Alcon employees to land at the smaller eye disease specialist.